Related publications

Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, Csajka C, Buclin T. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet 2011 [in press].

Buclin T, Widmer N, Biollaz J, Decosterd LA. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncol 2011;12(1): 9-11. Extract  -  PMID: 21111679.

Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011;117(8):e75-e87. Abstract  -  PMID: 20810928.

Widmer N, Gotta V, Haouala A, Decosterd LA. Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia. Leuk Res 2010;34(6):698-9. Extract  -  PMID: 20074797.

Gotta V, Widmer N, Decosterd LA, Csajka C, Duchosal MA, Chalandon Y, Heim D, Gregor M, Buclin T. Therapeutisches Drug-Monitoring von Imatinib. Schweiz Med Forum 2010;10(23):403–406.

Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877(22):1982-96. PMID: 19505856.

Widmer N, Decosterd LA, Leyvraz S, Duchosal M.A, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008;98(10):1633-1640. PMID: 18475296.

Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006;62(1):97-112. PMID: 16842382.